title: Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.
abstract: BACKGROUND
  Recombinant human interleukin 12 (rHuIL-12) regulates hematopoiesis and cell-mediated immunity. Based on these hematopoietic and immunomodulatory activities, a recombinant human IL-12 (rHuIL-12) is now under development to address the unmet need for a medical countermeasure against the hematopoietic syndrome of the acute radiation syndrome (HSARS) that occurs in individuals exposed to lethal radiation, and also to serve as adjuvant therapy that could provide dual hematopoietic and immunotherapeutic benefits in patients with cancer receiving chemotherapy. We sought to demonstrate in healthy subjects the safety of rHuIL-12 at single, low doses that are appropriate for use as a medical countermeasure for humans exposed to lethal radiation and as an immunomodulatory anti-cancer agent.
  
  
  METHODS
  Two placebo-controlled, double-blinded studies assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of rHuIL-12. The first-in-human (FIH) dose-escalation study randomized subjects to single subcutaneous injections of placebo or rHuIL-12 at 2, 5, 10, and 20 μg doses. Due to toxicity, dose was reduced to 15 μg and then to 12 μg. The phase 1b expansion study randomized subjects to the highest safe and well tolerated dose of 12 μg.
  
  
  RESULTS
  Thirty-two subjects were enrolled in the FIH study: 4 active and 2 placebo at rHuIL-12 doses of 2, 5, 10, 12, and 15 μg; 1 active and 1 placebo at 20 μg. Sixty subjects were enrolled in the expansion study: 48 active and 12 placebo at 12 μg dose of rHuIL-12. In both studies, the most common adverse events (AEs) related to rHuIL-12 were headache, dizziness, and chills. No immunogenicity was observed. Elimination of rHuIL-12 was biphasic, suggesting significant distribution into extravascular spaces. rHuIL-12 triggered transient changes in neutrophils, platelets, reticulocytes, lymphocytes, natural killer cells, and CD34+ hematopoietic progenitor cells, and induced increases in interferon-γ and C-X-C motif chemokine 10.
  
  
  CONCLUSIONS
  A single low dose of rHuIl-12 administered subcutaneously can elicit hematological and immune-mediated effects without undue toxicity. The safety and the potent multilineage hematopoietic/immunologic effects triggered by low-dose rHuIL-12 support the development of rHuIL-12 both as a radiation medical countermeasure and as adjuvant immunotherapy for cancer.
  
  
  BACKGROUND
  ClinicalTrials.gov: NCT01742221.
authors.forename: Mamata S
authors.initials: MS
authors.lastname: Gokhale
authors.forename: Vladimir
authors.initials: V
authors.lastname: Vainstein
authors.forename: Jamie
authors.initials: J
authors.lastname: Tom
authors.forename: Simmy
authors.initials: S
authors.lastname: Thomas
authors.forename: Chris E
authors.initials: CE
authors.lastname: Lawrence
authors.forename: Zoya
authors.initials: Z
authors.lastname: Gluzman-Poltorak
authors.forename: Nicholas
authors.initials: N
authors.lastname: Siebers
authors.affiliation: Neumedicines Inc, 133 North Altadena Drive, Suite 310, 91107-7342 Pasadena, CA, USA. basile@neumedicines.com.
authors.forename: Lena A
authors.initials: LA
authors.lastname: Basile
references.citation: J Leukoc Biol. 1994 Feb;55(2):280-8
references.pmid: 7905508
references.citation: Int Immunol. 1995 Jul;7(7):1135-45
references.pmid: 8527411
references.citation: J Exp Med. 1993 Aug 1;178(2):413-8
references.pmid: 7688022
references.citation: Blood. 2006 Jun 15;107(12):4650-7
references.pmid: 16507779
references.citation: Blood. 2003 Apr 15;101(8):3052-7
references.pmid: 12480696
references.citation: J Immunol. 1995 May 15;154(10):4950-5
references.pmid: 7537295
references.citation: Annu Rev Immunol. 2000;18:451-94
references.pmid: 10837066
references.citation: Clin Cancer Res. 1999 Dec;5(12):3983-9
references.pmid: 10632329
references.citation: J Immunol. 2001 Jun 1;166(11):6944-51
references.pmid: 11359856
references.citation: J Clin Invest. 1998 Dec 15;102(12):2035-40
references.pmid: 9854038
references.citation: PLoS One. 2012;7(2):e30434
references.pmid: 22383962
references.citation: Clin Cancer Res. 1998 May;4(5):1183-91
references.pmid: 9607576
references.citation: J Clin Pharmacol. 2005 Jun;45(6):649-58
references.pmid: 15901746
references.citation: Antivir Ther. 2007;12(5):741-51
references.pmid: 17713157
references.citation: Nephron. 2001 Jul;88(3):205-10
references.pmid: 11423750
references.citation: J Immunol. 1995 Dec 15;155(12):5684-9
references.pmid: 7499854
references.citation: J Leukoc Biol. 2003 Feb;73(2):213-24
references.pmid: 12554798
references.citation: J Hematol Oncol. 2014 Apr 06;7:31
references.pmid: 24708888
references.citation: Clin Cancer Res. 2002 Nov;8(11):3383-93
references.pmid: 12429625
references.citation: J Transl Med. 2008 May 19;6:26
references.pmid: 18489769
references.citation: J Neuropathol Exp Neurol. 2003 Mar;62(3):228-36
references.pmid: 12638727
references.citation: Leukemia. 1993 Sep;7(9):1381-8
references.pmid: 7690440
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5432-8
references.pmid: 15328181
references.citation: Clin Cancer Res. 2000 May;6(5):1678-92
references.pmid: 10815886
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4677-85
references.pmid: 17699845
references.citation: Clin Cancer Res. 2000 Jul;6(7):2661-9
references.pmid: 10914707
references.citation: J Immunol. 1994 Aug 1;153(3):930-7
references.pmid: 7517976
references.citation: J Exp Med. 1993 Oct 1;178(4):1223-30
references.pmid: 8104230
references.citation: Blood. 1994 Oct 1;84(7):2261-8
references.pmid: 7919344
references.citation: J Allergy Clin Immunol. 1998 Jul;102(1):86-93
references.pmid: 9679851
references.citation: J Immunother. 2004 Nov-Dec;27(6):460-71
references.pmid: 15534490
references.citation: Exp Hematol. 1989 Jan;17(1):10-6
references.pmid: 2535696
references.citation: J Immunol. 1994 Aug 15;153(4):1697-706
references.pmid: 7913943
references.citation: J Virol. 1997 Apr;71(4):3236-43
references.pmid: 9060687
references.citation: Leukemia. 1993 Sep;7(9):1374-80
references.pmid: 7690439
references.citation: Stem Cells. 1994 Mar;12(2):154-68
references.pmid: 7911046
references.citation: J Exp Med. 1989 Sep 1;170(3):827-45
references.pmid: 2504877
references.citation: Microvasc Res. 2002 Sep;64(2):326-33
references.pmid: 12204656
references.citation: Clin Cancer Res. 1997 Mar;3(3):409-17
references.pmid: 9815699
references.citation: Science. 1998 May 29;280(5368):1435-8
references.pmid: 9603733
references.citation: Clin Cancer Res. 2003 Jan;9(1):76-83
references.pmid: 12538454
references.citation: Clin Pharmacol Ther. 1999 Jun;65(6):615-29
references.pmid: 10391667
references.citation: J Infect Dis. 2003 Jun 15;187 Suppl 2:S370-84
references.pmid: 12792854
references.citation: Int J Mol Sci. 2010 Feb 26;11(3):789-806
references.pmid: 20479986
references.citation: Blood. 1994 Jan 1;83(1):92-8
references.pmid: 7506084
references.citation: Ann N Y Acad Sci. 1996 Oct 31;795:xiii-xix
references.pmid: 8958911
references.citation: J Immunol. 1991 May 1;146(9):3074-81
references.pmid: 1673147
references.citation: Int Immunol. 1994 Jan;6(1):157-67
references.pmid: 7908534
references.citation: Am J Gastroenterol. 2007 Jul;102(7):1499-509
references.pmid: 17459027
references.citation: Clin Exp Immunol. 2006 Sep;145(3):535-44
references.pmid: 16907924
references.citation: Br J Haematol. 2000 Oct;111(1):104-11
references.pmid: 11091188
references.citation: Nat Rev Neurosci. 2005 Jun;6(6):484-94
references.pmid: 15928718
references.citation: Exp Hematol. 2007 Feb;35(2):203-13
references.pmid: 17258069
references.citation: Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8
references.pmid: 8171022
references.citation: Blood. 1999 Aug 1;94(3):902-8
references.pmid: 10419880
references.citation: Blood. 1995 May 1;85(9):2371-6
references.pmid: 7727771
references.citation: Cancer Res. 2001 Feb 15;61(4):1517-21
references.pmid: 11245459
references.citation: Am J Pathol. 2010 Sep;177(3):1244-54
references.pmid: 20696776
references.citation: J Clin Oncol. 2003 Jul 1;21(13):2564-73
references.pmid: 12829677
references.citation: J Interferon Cytokine Res. 2000 Apr;20(4):391-401
references.pmid: 10805374
references.citation: Ann Surg. 2000 Feb;231(2):253-61
references.pmid: 10674618
references.citation: Cancer Res. 2000 Jul 1;60(13):3559-68
references.pmid: 10910069
references.citation: Cytokine Growth Factor Rev. 2002 Apr;13(2):155-68
references.pmid: 11900991